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Abstract
Background: The Rubiaceae family has played a significant role in drug discovery by providing molecules with
potential use as templates for the development of therapeutic drugs. This study was designed to study the in
vitro synergistic effect of six Rubiaceae species in combination with a known anti-TB drug. The antioxidant and
anti-inflammatory activity of these species were also evaluated to investigate additional benefits in antimycobacterial
treatment.
Methods: The checkerboard method was used to determine the antimycobacterial synergistic activity of plant
extracts combined with rifampicin. The antioxidant activity of extracts was determined by the 2,2-diphenyl-
1-picrylhydrazyl (DPPH) method. Anti-inflammatory activity via inhibition of nitric oxide (NO) production was
performed in LPS-activated RAW 264.7 macrophages using the Griess assay.
Results: Combination of rifampicin with the crude extracts resulted in a 4 to 256-fold increase of activity
of extracts. The crude extract of Cremaspora triflora produced the best synergistic effect with rifampicin, with
a fractional inhibitory concentration (FIC) index of 0.08 against Mycobacterium aurum. Extracts of Psychotria
zombamontana had the best antioxidant activity with an IC50 value of 1.77 μg/mL, lower than the IC50 of
trolox and ascorbic acid (5.67 μg/mL and 4.66 μg/mL respectively). All the extracts tested inhibited nitric oxide (NO)
production in a concentration dependent manner with the percentage of inhibition varying from 6.73 to 86.27 %.
Conclusion: Some of the Rubiaceae species investigated have substantial in vitro synergistic effects with rifampicin
and also good free radical scavenging ability and anti-inflammatory activity. These preliminary results warrant further
study on these plants to determine if compounds isolated from these species could lead to the development
of bioactive compounds that can potentiate the activity of rifampicin even against resistant mycobacteria.
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Background
The emergence of drug resistant tuberculosis (TB)
strains (including multi drug resistant, MDR and ex-
tremely drug resistant, XDR) has reduced the efficacy of
first-line anti-TB drugs. Therefore, there is an urgent
need to design drugs that can act in synergy with previ-
ously potent anti-TB drugs. The implementation of com-
bination therapy is of great importance for the treatment
of infectious diseases, as monotherapy is often associated
with an increase in the development of resistance. In
order to improve the cure rate of infectious disease and
curb the upsurge of resistance, combination therapy is
encouraged, as has been shown with the multidrug ap-
proach used to treat tuberculosis (Isoniazid, Rifampicin,
Pyrazinamide and Ethambutol). Without such combin-
ation therapy, the death rate of infected patients could
have reached global epidemic proportions [1].
Most in vitro studies determine the therapeutic effect
of new drugs as single agents, but in clinical practice to
prevent the development of drug resistance, a combin-
ation of various drugs is imperative [2]. Combination
studies with natural products from plants and synthetic
drugs are limited to relatively few reports. Therefore,
evaluating the in vitro effect of bioactive extracts or
compounds with the classic anti-TB drugs is necessary
and may lead to more effective treatment of TB [3, 4].
One of the manifestations of inflammation is oxidative
stress, and the pathways that generate the mediators of
inflammation are all induced by oxidative stress [5].
Most of the potentially harmful effects of oxygen are
due to the formation of reactive oxygen species (ROS).
The role played by the reactive oxygen intermediates
during TB infection is not fully understood, but it is
known that hydrogen peroxide produced by macro-
phages which have been activated by cytokines has
mycobactericidal activity [6]. Excess reactive oxygen spe-
cies (ROS) generated could however, lead to inflamma-
tion, and antioxidant substances that can scavenge and
eliminate ROS may be useful in preventing or minimiz-
ing oxidation-related diseases such as TB [7]. Costantino
et al. [8] reported several studies showing the correlation
between antioxidant properties of plants with oxidative
stress defence.
Nitric oxide (NO) plays a significant role during the
host defence response against different pathological or-
ganisms such as bacteria, viruses, parasites and fungi [9].
NO is important in regulating diverse pathophysiological
process in the body under normal physiological condi-
tions [10]. It is a free radical involved in many biological
processes, with the ability to enhance the bactericidal ac-
tivity of activated macrophages [11]. In case of treatment
failure or of infection with resistant strains, mycobac-
teria persist in the macrophages of the host for a long
period. This can lead to an overexpression of
inflammatory mediators including nitric oxide and fur-
ther generate oxidative stress due to an imbalance be-
tween pro-oxidant and antioxidant systems. Furtermore,
excessive production of NO may lead to potential tissue
damage associated with acute and chronic inflammation
[12]. Many researchers have demonstrated the potential
of medicinal plant extracts to scavenge free radicals and
modulate inflammatory reactions [13, 14]. The mamma-
lian immune system combats pathogens through acti-
vated macrophages, thereby providing microbicidal
activity before the initiation of various pro-inflammatory
mediators such as NO [10]., Lipopolysaccharide (LPS) a
Gram-negative bacterial cell wall component is a good
activator of macrophages, and is also involved in the
production of pro-inflammatory cytokines [15]. There-
fore, much attention is being given to the invention
of drugs which can act as potent inhibitors of NO
production (such as that detected in LPS stimulated
RAW 264.7 cells) as a possible treatment for chronic
inflammatory disease [16]. Plant products have been
used in the development of new drugs, and they con-
tinue to play an important role in the discovery and
development of new drugs [17]. Therefore, plant
products that can inhibit the production of NO may
be a potential therapy for those diseases in which in-
flammation plays a role [18].
Various species from the Rubiaceae family have proven
to be a promising source of new bioactive substances
which may lead to the development of new products as
active molecules or drug prototypes due to their struc-
tural diversity and pharmacological activities [19]. One
peculiar characteristic of this family is that they contain
a wide range of secondary metabolites such as alka-
loids, flavonoids, terpenes, anthraquinones and cou-
marins having good pharmacological properties [20].
These classes of secondary metabolites have been as-
sociated with antimicrobial, anti-malarial, hepatopro-
tective, antioxidant, and many other interesting
biological activities [21].
In a previous study, six species from the Rubiaceae
family, namely Cephalanthus natalensis, Cremaspora tri-
flora, Oxyanthus speciosus, Pavetta lanceolata, Psycho-
tria capensis and Psychotria zombamontana were shown
to have good antimycobacterial activity [22]. These spe-
cies were selected for further study to determine their
synergistic activity with a known antimycobacterial
drug., The antioxidant and nitric oxide inhibitory prop-
erties were also determined in an effort to gain more
insight into their potential mechanism of action.
Methods
Plant collection
The leaves of plants were collected in the Pretoria
National Botanical Garden in terms of a signed material
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transfer agreement. The plant materials were identified
by the curator and labelled. Voucher specimens were
kept in the HGWJ Schweickerdt Herbarium of the
University of Pretoria (PRU) (Table 1). The leaves were
air-dried at room temperature, ground to a fine powder
in a Macsalab mill (Model 200 LAB, Eriez, Bramley,
Johannesburg, South Africa) and stored in closed glass
containers in the dark until needed. Acetone was se-
lected as the extracting solvent for the dried leaf powder
owing to its ability to extract a wide range of compounds
and its low toxicity in the antimicrobial bioassay [23].
Ground leaf material was extracted by acetone in a ratio
of 10:1 (v:m), evaporated to dryness and made up to a
concentration of 10 mg/mL.
Mycobacterial culture
Antimycobacterial activity was tested against two
non-tuberculous mycobacteria (NTM): Mycobacterium
smegmatis (ATCC 1441) and Mycobacterium aurum
(NCTC 10437), as well as against a M. tuberculosis
field strain (TB 8104) which was isolated from a
waterbuck and genetically characterized using variable
number of tandem repeat typing based on a 13-locus
VNTR panel [24].
In vitro synergistic antimycobacterial activity
The effect of combinations of the acetone extracts of
Cremaspora triflora, Cephalanthus natalensis, Oxy-
anthus speciosus, Pavetta lanceolata, Psychotria capensis
and Psychotria zombamontana with rifampicin (RIF,
Sigma) against three mycobacteria were determined
using the checkerboard method [25]. Rifampicin was
dissolved in DMSO (0.25 %). The Fractional Inhibitory
Concentration (FIC) of each drug was calculated by div-
iding the concentration of the extract present in that
well in combination, where complete inhibition of
growth of the microorganism was observed, by the MIC
of that extract alone to inhibit the microorganism. All
assays were performed in triplicate. The ΣFIC was then
calculated for each test sample independently as speci-
fied in the following equations:
FIC (a) =MIC (a) in combination with (b)/ MIC (a)
alone
FIC (b) =MIC (b) in combination with (a)/ MIC (b)
alone
The sum of the FIC or FIC index is thus calculated as:
ΣFIC = FIC (a) + FIC (b)
The interpretations of the ΣFICs were as follows: ΣFIC ≤
0.5 = synergistic; >0.5–1.0 = additive; >1.0–≤4.00 = non-
interactive and >4.0 = antagonistic [1].
DPPH assay
The DPPH radical-scavenging activity was determined as
previously described [7]. Ascorbic acid and trolox were
used as positive controls, methanol as negative control
and extract without DPPH as blank. Results were
expressed as percentage reduction of the initial DPPH
absorption in relation to the control. The concentration
of extract leading to 50 % reduction of DPPH (IC50) was
also determined.
Inhibition of nitric oxide (NO) production
The NO production inhibitory activity of plant extracts
was evaluated in the LPS-activated mouse macrophage
cell line RAW 264.7 as previously described [7]. Validity
of the assays was shown by using untreated cells as
negative control, LPS-stimulated cells as positive control
and additionally a cell group as reduction control group
with LPS-stimulated cells, co-incubated together with
quercetin used as an inhibitor of NO.
Statistical analysis
All experiments were conducted in triplicate and values
expressed as mean ± standard deviation. Statistical ana-
lysis was performed using one way ANOVA and results
were compared using the Fisher’s least significant differ-
ence (LSD) at a 5 % significance level.
Results
The results of the combination of the six crude extracts
with rifampicin against M. smegmatis, M. aurum and M.
tuberculosis (8104) showed varying degrees of synergistic
to non-interactive antimycobacterial effects. Upon
addition of sub-minimal inhibitory concentrations of the
acetone crude extracts to rifampicin, reduction of the
MICs of the anti-TB drug ranged from 2-fold to 4-fold
(ΣFIC = 0.5–1), 2-fold to 64-fold (ΣFIC = 0.08–2) and 2-
fold to 64-fold (ΣFIC =0.19–1) for M. smegmatis, M.
aurum and M. tuberculosis respectively (Table 1). The
MIC values of the crude extracts against the three tested
mycobacteria were reduced to varying degrees. Cremas-
pora triflora and Pavetta lanceolata extract MIC values
were decreased 16-fold to 256-fold in combination with
rifampicin (ΣFIC = 0.08–0.5) against M. aurum. The
crude extract of Pavetta lanceolata also showed some
synergistic to additive effect.
Regarding antioxidant activity, plant extracts with
IC50 < 50 μg/mL are considered to have significant anti-
oxidant activity while samples with IC50 > 50 μg/mL are
classified as having moderate antioxidant activity [26].
Compounds with IC50 < 10 μg/mL are considered to
have significant antioxidant capacity while 10 < IC50 <
20 μg/mL are considered moderate and IC50 > 20 μg/mL
are said to possess low antioxidant activity [27]. The
lower the IC50 value of an extract, the higher its antioxi-
dant activity. The crude extract of Psychotria zomba-
montana had the best antioxidant activity among the six
tested extracts with an IC50 value of 1.77 μg/mL
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Table 1 Synergistic activity of extracts from six Rubiaceae species and rifampicin against Mycobacterium species
Extract/rifampicin Mycobacterial
strains
MIC (μg/ml) FICa Interpretation
Individualb Combinationc Individual Index
Cephalanthus natalensis/rifampicin M. smegmatis 17/16 0.531/8 0.03/0.5 0.53 Synergy
0.133/8 0.008/0.5 0.51 Synergy
0.066/8 0.004/0.5 0.5 Synergy
M. aurum 100/78 50/1.21 0.5/0.02 0.52 Synergy
50/9.75 0.5/0.13 0.63 Additive
1.56/19.5 0.02/0.25 0.27 Synergy
M. tuberculosis 40/9 40/1.125 1/0.125 1.125 Non-interactive
5/2.25 0.125/0.25 0.38 Synergy
2.5/2.25 0.063/0.25 0.31 Synergy
Cremaspora triflora/rifampicin M. smegmatis 23/16 11.5/8 0.5/0.5 1 Additive
5.7/8 0.25/0.5 0.75 Additive
2.88/8 0.125/0.5 0.63 Additive
M. aurum 100/78 6.25/1.21 0.063/0.016 0.08 Synergy
50/2.43 0.5/0.031 0.53 Synergy
25/4.87 0.25/0.063 0.31 Synergy
M. tuberculosis 160/9 40/0.14 0.25/0.016 0.27 Synergy
20/0.56 0.125/0.062 0.19 Synergy
10/1.125 0.062/0.125 0.19 Synergy
Oxyanthus speciosus/rifampicin M. smegmatis 80/16 20/8 0.25/0.5 0.75 Additive
10/8 0.125/0.5 0.63 Additive
5/8 0.06/0.5 0.56 Additive
M. aurum 60/78 60/78 1/1 2 Non-interactive
30/78 0.5/1 1.5 Non-interactive
15/78 0.25/1 1.25 Non-interactive
M. tuberculosis 170/9 85/2.25 0.5/0.25 0.75 Additive
21.25/2.25 0.125/0.25 0..38 Synergy
5.31/2.25 0.031/0.25 0.28 Synergy
Pavetta lanceolata/rifampicin M. smegmatis 12/16 6/8 0.5/0.5 1 Additive
3/8 0.25/0.5 0.75 Additive
1.5/8 0.125/0.5 0.63 Additive
M. aurum 100/78 6.25/39 0.063/0.5 0.56 Additive
0.781/39 0.008/0.5 0.51 Synergy
0.391/39 0.004/0.5 0.5 Synergy
M. tuberculosis 120/9 60/2.25 0.5/0.25 0.75 Additive
30/4.5 0.25/0.5 0.75 Additive
7.5/4.5 0.063/.05 0.56 Additive
Psychotria capensis/rifampicin M. smegmatis 60/16 30/8 0.5/0.5 1 Additive
15/8 0.25/0.5 0.75 Additive
7.5/8 0.125/0.5 0.63 Additive
M. aurum 120/78 30/19.5 0.25/0.25 0.5 Synergy
15/39 0.13/0.5 0.63 Additive
3.75/39 0.03/0.5 0.53 Synergy
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compared to trolox and ascorbic acid (with IC50
values of 5.67 μg/mL and 4.66 μg/mL respectively).
Based on the above cut-off criteria, Psychotria capen-
sis also had good antioxidant activity with an IC50
value of 29.73 μg/mL while other extracts had moder-
ate to weak antioxidant capacity (IC50 values ranging
from 68.64–259.7 μg/mL).
As shown in Table 2, all the extracts had a dose
dependent inhibition of NO production at concentra-
tions of 6.25, 12.5, 25 and 50 mg/mL. The crude acetone
extract of Psychotria capensis had the best inhibitory ac-
tivity on NO production (86.27 %), but this is most likely
due to cytotoxic effects of the extract on the RAW 264.7
macrophage cell line. Percentage cell viability at 50 and
25 μg/mL respectively was as low as 4.44 % and 28.31 %.
The acetone extract of Psychotria capensis has been re-
ported for its cytotoxic effect on C3A human liver and
Vero kidney cells [22]. Pavetta lanceolata also had good
anti-inflammatory activity by inhibiting the production
of NO by 70 % with no concomitant cytotoxic effect on
RAW 264.7 macrophages.
Discussion
Spontaneous genetic mutations in Mycobacterium tuber-
culosis may lead to the emergence of drug resistant
strains following inconsistent or inappropriate single
drug therapy using selected anti-TB drugs [28]. Rifampi-
cin is one of the most effective first-line TB drugs which
is active against drug-susceptible TB, but the emergence
of resistant strains is threatening the continued efficacy
of this drug. Synergistic effects can occur if the constitu-
ents of an extract affect different targets or interact with
one another in order to enhance the bioavailability of
one or several substances of an extract [29]. The acetone
extract of Cremaspora triflora in combination with
rifampicin had the best fractional inhibitory
concentration (ΣFIC = 0.08) showing a synergistic effect
and leading to a 64-fold reduction in the MIC of rifam-
picin i.e. a 64-fold increase in the antimycobacterial ac-
tivity. Oxyanthus speciosus in combination with
rifampicin had a non-interactive effect (ΣFIC = 2) against
M. aurum. Based on this assay, only a two-fold reduc-
tion in the MIC of rifampicin was observed against M.
smegmatis. Encouragingly, no antagonist effect was ob-
served using the different combinations against all the
tested strains. Synergy in terms of natural product com-
binations may be affected by many factors such as:
pharmacokinetics, physicochemical properties, complex
multi-target effects or therapeutic approaches [29].
It has been reported that the antioxidant activity of
plant materials is well correlated with the content of
their phenolic compounds [30]. Different studies have
also shown a positive correlation between phenolic com-
pounds and terpene concentration with antimicrobial ac-
tivity [31, 32].
Of the six extracts tested, Psychotria zombamonatana
and Psychotria capensis had good antioxidant activity.
Others had only moderate to weak free radical scaven-
ging capacity, with Oxyanthus speciosus having the low-
est antioxidant activity. Extracts with good inhibitory
activity on NO production and low cytotoxicity are more
useful for potential therapeutic application. Anti-
inflammatory activity of plant extracts above 70 % at a
concentration of 250 μg/ml is considered significant
[33]. The six crude extracts screened in this study all led
to dose-dependent NO inhibition. However, when com-
pared with the activity of quercetin, the extracts did not
meaningfully inhibit the production of NO, except for
the acetone extract of Psychotria capensis. This extract
had toxicity to the LPS-stimulated RAW 264.7 macro-
phage cell line, which limits its usefulness. The synergis-
tic effect of many compounds in natural products
Table 1 Synergistic activity of extracts from six Rubiaceae species and rifampicin against Mycobacterium species (Continued)
M. tuberculosis 630/9 315/4.5 0.5/0.5 1 Additive
157.5/4.5 0.25/0.5 0.75 Additive
78.75/4.5 0.125/0.5 0.63 Additive
Psychotria zombamontana/rifampicin M. smegmatis 40/16 10/8 0.25/0.5 0.75 Additive
5/8 0.125/0.5 0.63 Additive
2.5/8 0.06/0.5 0.56 Additive
M. aurum 80/78 20/19.5 0.25/0.25 0.5 Synergy
10/19.5 0.125/0.25 0.38 Synergy
5/19.5 0.063/0.25 0.31 Synergy
M. tuberculosis 160/9 80/2.25 0.5/0.25 0.75 Additive
40/2.25 0.25/0.25 0.5 Synergy
20/2.25 0.125/0.25 0.38 Synergy
aFIC fractional inhibitory concentration for individual sample FIC index + = FIC (a) + FIC (b). bMIC minimum inhibitory concentration for individual sample;
cMIC of samples in combination
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enhances their antioxidant properties. The acetone ex-
tract of Psychotria capensis showed a synergistic antimy-
cobacterial effect in combination with rifampicin and
also had good antioxidant activity while inhibiting the
production of NO.
Antioxidants act by scavenging free radicals such as
reactive oxygen species, hydroxyl radicals and nitric
oxide while anti-inflammatory mediators act by modu-
lating the activities of pro-inflammatory enzymes and cy-
tokines. In inflammation, nitric oxide (NO) acts as a
pro-inflammatory mediator and is synthesized by indu-
cible nitric oxide synthase (iNOS) in response to pro-
inflammatory agents such as lipopolysaccharide (LPS)
[34]. The inhibitory activity of NO production by medi-
cinal plants may originate from the inhibition of iNOS
enzyme activity and/or expression of nitric oxide syn-
thase [35]. Many natural compounds from medicinal
plants are known inhibitors of iNOS expression in LPS-
activated macrophages [36]. No report could be found
on the inhibitory activity of the Rubiaceae plant extracts
tested in this study on NO synthesis in LPS-activated
RAW 264.7 cells. The selected plant species have been
reported for their antimycobacterial activities against
mycobacteria but possess weak antioxidant and anti-
inflammatory activity. Because of the role rifampicin
plays in the treatment of TB, researchers are interested
in compounds that can display synergistic activity with
this efficacious anti-TB drug in order to increase both
therapeutic efficacy and reduce toxicity commonly
observed by this drug [37, 38].
Table 2 Antioxidant and NO production inhibitory activity and cell viability of extracts from six Rubiaceae species
Samples Concentration (μg/mL) NO (μM) % NO inhibition Cell viability DPPH (IC50 in μg/mL) Voucher no
Cephalanthus natalensis 50 1.26 ± 0.14 53.81 104.67 68.64 ± 0.20a PRU 120872
25 1.32 ± 0.09 51.39 100.84
12.5 1.80 ± 0.08 33.95 90.02
6.25 2.34 ± 0.06 14.10 76.19
Cremaspora triflora 50 1.97 ± 0.16 27.66 96.70 90.02 ± 0.10b 114710
25 2.43 ± 0.13 10.70 105.20
12.5 2.48 ± 0.08 8.77 104.25
6.25 2.90 ± 0.06 6.73 118.31
Oxyanthus speciosus 50 1.63 ± 0.06 40.25 109.84 259.7 ± 0.23c PRU 120873
25 1.57 ± 0.07 42.19 97.04
12.5 1.77 ± 0.12 34.92 91.61
6.25 1.94 ± 0.15 28.63 88.82
Pavetta lanceolata 50 0.80 ± 0.16 70.77 101.73 138.94 ± 0.18d PRU 120874
25 1.26 ± 0.10 53.81 112.10
12.5 1.84 ± 0.13 32.50 116.49
6.25 2.52 ± 0.10 7.31 123.03
Psychotria capensis 50 0.37 ± 0.05 86.27 4.44 29.73 ± 0.22e PRU 120875
25 1.08 ± 0.77 60.11 28.31
12.5 2.97 ± 0.22 9.16 75.40
6.25 3.22 ± 0.23 18.36 115.71
Psychotria zombamontana 50 2.19 ± 0.10 19.42 114.53 1.77 ± 0.13f PRU 120867
25 2.02 ± 0.20 25.72 93.32
12.5 2.05 ± 0.14 24.75 91.92
6.25 2.40 ± 0.10 11.67 76.91
Quercetin 25 0.35 ± 0.10 95.54 49.33 nd
12.5 0.30 ± 0.05 96.14 60.69
6.25 0.69 ± 0.08 91.08 73.76
3.12 2.50 ± 0.48 73.76 73.10
Trolox nd nd nd nd 5.67 ± 0.24f nd
Ascorbic acid nd nd nd nd 4.66 ± 0.25h nd
Values with different letters are significantly different at p < 0.05
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Despite the weak antioxidant and anti-inflammatory
activities, these plant extracts were able to decrease the
MIC of rifampicin, thereby enhancing the mycobacterici-
dal activity of this drug. The synergistic interaction ob-
served in this study may be important, as rifampicin
plays a pertinent role in reducing the duration of treat-
ment for TB, thereby enhancing patients’ compliance to
prevent the development of drug resistant cases.
Furthermore, reducing the dosage of rifampicin by using
different drug combinations could reduce adverse effects
observed during administration of this antimycobacterial
drug.
Conclusion
This study investigated the in vitro synergistic activity of
six Rubiaceae species in combination with the first-line
antitubercular drug rifampicin. All the screened crude
extracts produced synergistic to additive effects at differ-
ent concentrations when combined with rifampicin but
no antagonist effect was observed. A promising observa-
tion was the lack of cytotoxicity observed with some of
the extracts. Whole animal studies are required to con-
firm the low toxicity of the extracts. The findings from
this study are preliminary but are sufficient to warrant
further study on these Rubiaceae species, as compounds
isolated from these species could lead to the develop-
ment of novel antimycobacterial compounds.
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